Pacad Investment Ltd. trimmed its holdings in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 64.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 27,383 shares of the biopharmaceutical company’s stock after selling 49,400 shares during the period. Pacad Investment Ltd.’s holdings in Achillion Pharmaceuticals were worth $126,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of ACHN. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Achillion Pharmaceuticals by 3.6% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 800 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Achillion Pharmaceuticals by 18.6% during the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 4,144 shares during the period. Teza Capital Management LLC bought a new position in shares of Achillion Pharmaceuticals during the 1st quarter valued at $131,000. TradeLink Capital LLC bought a new position in shares of Achillion Pharmaceuticals during the 2nd quarter valued at $132,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in shares of Achillion Pharmaceuticals during the 1st quarter valued at $138,000. Institutional investors and hedge funds own 74.12% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Holdings Reduced by Pacad Investment Ltd.” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/17/achillion-pharmaceuticals-inc-achn-holdings-reduced-by-pacad-investment-ltd.html.

Several equities analysts have recently weighed in on ACHN shares. Ladenburg Thalmann Financial Services lowered their price target on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. BidaskClub cut Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Chardan Capital lowered their price target on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday, August 9th. Finally, Robert W. Baird reissued a “neutral” rating and set a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $6.50.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at 3.70 on Friday. Achillion Pharmaceuticals, Inc. has a one year low of $3.15 and a one year high of $9.19. The company’s market capitalization is $506.02 million. The company has a 50-day moving average price of $4.50 and a 200-day moving average price of $4.20.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same quarter in the previous year, the business earned ($0.14) EPS. Analysts expect that Achillion Pharmaceuticals, Inc. will post ($0.66) earnings per share for the current fiscal year.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.